Sabby Management’s Briacell Therapeutics BCTX Stock Holding History

Sabby Management’s Portfolio BCTX Stock Details BCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$310K	Buy	+73,915	New	+$344K	0.69%	11
2025 Q3	–	Sell	-3,953	Closed	-$116K	–	43
2025 Q2	$116K	Buy	+3,953	New	+$144K	0.21%	31
2024 Q2	–	Sell	-228	Closed	-$97.9K	–	42
2024 Q1	$97.9K	Buy	+228	New	+$126K	0.06%	34
2023 Q1	–	Sell	-79	Closed	-$52K	–	95
2022 Q4	$52K	Sell	79 -548	-87%	-$464K	0.05%	85
2022 Q3	$528K	Buy	627 +243	+63%	+$244K	0.67%	36
2022 Q2	$332K	Buy	384 +184	+92%	+$182K	0.23%	55
2022 Q1	$304K	Buy	+200	New	+$237K	0.05%	84
2021 Q3	–	Sell	-1,307	Closed	-$1.04M	–	184
2021 Q2	$1.04M	Buy	1,307 +239	+22%	+$149K	0.15%	78
2021 Q1	$618K	Buy	+1,068	New	+$581K	0.12%	99

Other funds holding BCTX

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

LCM

LuminArx Capital Management New York $136M AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Sabby Management's BCTX Position: Q1 2026 in Review

Sabby Management opened a new position in Briacell Therapeutics (BCTX) in Q1 2026: 73,915 shares worth $310K. The stake represents 0.69% of the portfolio and ranks #11 among its holdings. This is a return to the name: Sabby Management previously reported a position in BCTX as recently as Q2 2025.

Sabby Management first reported a position in BCTX in Q1 2021 and has held it in 9 quarters since. The position peaked at $1.04M in Q2 2021. 16 funds tracked by Wall St. Rank hold BCTX as of Q1 2026.

Sabby Management held 73,915 shares of Briacell Therapeutics worth $310K as of Q1 2026.
Briacell Therapeutics was a new Sabby Management position in Q1 2026.
Briacell Therapeutics made up 0.69% of Sabby Management's portfolio in Q1 2026, its #11 holding.
Sabby Management first reported a position in Briacell Therapeutics in Q1 2021 and has held it in 9 quarters since.
Sabby Management's Briacell Therapeutics position peaked at $1.04M in Q2 2021.
16 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q1 2026.

Based on Sabby Management's 13F filing for Q1 2026, filed 15 May 2026.